Primerica delivered solid third-quarter results, with total revenues increasing by 8% to $839.9 million and net income rising by 6% to $206.8 million. Diluted EPS grew by 11% to $6.35, driven by strong Investment and Savings Products sales and steady growth in Term Life premiums. The company also reported record ISP client asset values and a growing life-licensed sales force.

Primerica delivered robust financial results in the second quarter of 2025, with total revenue reaching $793.3 million and diluted adjusted operating EPS increasing by 10% year-over-year to $5.46. The company saw significant growth in Investment and Savings Products sales and client asset values, alongside a 5% increase in its life-licensed sales force.

Primerica reported $804.8 million in revenue and $169.1 million in net income for Q1 2025, driven by record Investment and Savings Products sales, growth in the life-licensed sales force, and steady performance in Term Life Insurance. Diluted EPS grew 19% year-over-year to $5.05.

Primerica delivered solid results in Q4 2024, with 12% YoY revenue growth, driven by strong Investment and Savings Products (ISP) sales and higher client asset values. Net income rose 9%, while adjusted EPS increased by 17%. The company also expanded its life-licensed sales force and raised its dividend by 16%.

Primerica reported strong third-quarter results, with an 11% increase in total revenues to $774.1 million and a 31% increase in net earnings per diluted share to $5.72. The company benefited from sustained recruiting momentum, growth in new life-licensed representatives, and favorable equity market conditions.

Primerica reported a net income of $1.2 million, or $0.03 per diluted share, impacted by the exit of the Senior Health business. However, the core business showed strength with adjusted net operating income increasing 12% to $162.7 million and adjusted operating earnings per diluted share growing 18% year-over-year to $4.71. Total revenue increased 17% to $803.4 million, including $50 million from an insurance claim.

Primerica reported an 8% increase in total revenues, reaching $742.8 million for Q1 2024. Net income increased by 8% to $137.9 million, and earnings per diluted share increased by 14% to $3.93. The company saw growth in its Term Life and Investment and Savings Products segments, but experienced weakness in the Senior Health business.

Primerica reported a 6% increase in total revenues, reaching $726.3 million, and a 9% increase in earnings per diluted share (EPS) to $4.30. The life-licensed sales force grew to a record 141,572, up 5% year-over-year. Investment and Savings Product sales increased by 13%, and client asset values rose by 15%.

Primerica reported a strong third quarter in 2023, with a 6% increase in total revenues to $710.9 million and a 91% increase in net income to $152.1 million. Adjusted operating EPS increased by 14% to $4.28. The life-licensed sales force grew by 4% year-over-year, and both the Term Life and Investment and Savings Products segments showed solid growth.

Primerica reported a 3% increase in total revenues, reaching $688.4 million, and a 13% increase in net income attributable to Primerica, amounting to $144.5 million. Earnings per diluted share increased by 20% to $3.97. The company's ROE was 29.2% for the quarter.

Primerica reported largely unchanged total revenues of $690.0 million compared to Q1 2022. Net income attributable to Primerica increased 9% to $125.1 million, with earnings per diluted share up 16% to $3.38. The company saw growth in term life sales and distribution, with positive net flows in the Investment and Savings Products business.

Primerica reported a decrease in GAAP revenues by 5% to $686.9 million. Net income was $131.8 million, with earnings per diluted share at $3.54 and a return on equity of 31.6%. The life-licensed sales force grew by 4.4% to a record 135,208 representatives, and term life net premiums increased by 5%.

Primerica reported a decrease in total revenues by 3% to $673.3 million and a net income decrease of 54% to $51.8 million compared to Q3 2021. Adjusted operating EPS increased by 1% to $3.02. The results reflect a non-cash goodwill impairment charge of $60.0 million. Despite market volatility, the company saw growth in its life-licensed sales force and continued progress in the term life insurance segment.

Primerica's Q2 2022 results showed a mixed performance. While total revenues increased by 2%, net income and EPS decreased by 16% and 13%, respectively. The Term Life segment remained strong, but the Investment and Savings segment was impacted by market correction. The company is focusing on sales force momentum and anticipates a better second half of the year.

Primerica's Q1 2022 results showed an 8% increase in total revenues to $691.2 million, but a 17% decrease in net income to $81.4 million. EPS decreased by 16% to $2.06. The company faced headwinds in the Senior Health segment, while the Term Life and Investment and Savings Products segments showed revenue growth.

Primerica reported a 21% increase in total revenues, reaching $724.1 million, and a 20% increase in diluted adjusted operating EPS to $2.94. The company faced headwinds in its Senior Health segment, resulting in a $76 million goodwill impairment charge. The Board of Directors approved an increase of $50 million to the share repurchase program.

Primerica reported a 22% increase in total revenues, reaching $693.2 million, for the third quarter of 2021. Net income attributable to Primerica was $112.4 million, with earnings per diluted share (EPS) at $2.82. The company's Investment and Savings Products sales increased by 52%, and client asset values reached $92 billion. The acquisition of e-TeleQuote impacted results with revenues of $22.9 million and a net loss of $4.6 million.

Primerica reported a strong second quarter in 2021, with total revenues increasing by 25% to $654.7 million. Net income rose by 26% to $128.2 million, and diluted earnings per share increased by 28% to $3.22. The company saw robust growth in investment and savings products sales, which surpassed $3 billion, and maintained strong demand for term life insurance policies.

Primerica reported a strong first quarter in 2021, with total revenues increasing by 21% to $637.7 million and net income rising by 35% to $97.9 million. The company saw significant growth in investment and savings products sales, as well as issued term life policies. Earnings per share increased by 41% to $2.46, and the return on equity reached 21.1%.

Primerica reported a 12% increase in total revenues to $598.3 million and a 13% increase in earnings per diluted share (EPS) to $2.52 for Q4 2020. The company's life-licensed sales force grew by 3% to 134,907, and investment and savings products sales increased by 4% to $2.1 billion. The Board of Directors approved a share repurchase program totaling $300 million and an 18% increase in dividends.

Primerica reported a strong third quarter in 2020, with a 9% increase in total revenues to $568.5 million and a 17% increase in net income to $112.1 million. Earnings per diluted share increased by 23% to $2.81. The company benefited from strong demand for protection products and an increase in average client asset values.

Primerica reported a 4% increase in total revenues to $525.8 million and a 4% increase in net income to $101.5 million compared to Q2 2019. Earnings per diluted share increased 10% to $2.51, with ROE remaining robust at 25.6%. The company saw strong term life sales and client asset values recovered, while investment and savings product sales declined due to market uncertainty.

Primerica reported a 6% increase in total revenues, driven by strong sales in Term Life and Investment and Savings Products. However, net income and EPS decreased due to pre-tax realized losses on the invested asset portfolio and mark-to-market adjustments. Adjusted operating EPS increased by 18%.

Primerica reported a strong fourth quarter in 2019, with significant growth in revenues and earnings per share. Total revenues increased by 9% to $532.0 million, and net income rose by 8% to $93.6 million. EPS increased by 13% to $2.24. The company saw record investment product sales and client asset values, driven by solid financial results in both the Term Life and Investment and Savings Products segments.